Wells Fargo Has Decided To Downgrade Jounce Therapeutics Inc (JNCE) Shares

May 18, 2018 - By Tina Thibodeau

Jounce Therapeutics Inc (JNCE) Receives a Downgrade

In an analyst report revealed to investors and clients on Thursday, 17 May, Wells Fargo cut their rating for shares of Jounce Therapeutics Inc (JNCE) to a Hold and they now have a $13.0000 target price per share on the stock. Wells Fargo’s target price per share would suggest a possible upside of 13.54 % from the stock close price of Jounce Therapeutics Inc (JNCE).

Jounce Therapeutics, Inc. (NASDAQ:JNCE) Ratings Coverage

Among 2 analysts covering Jounce Therapeutics Inc (JNCE), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Jounce Therapeutics Inc has $35.0 highest and $33 lowest target. $34’s average target is 196.94% above currents $11.45 stock price. Jounce Therapeutics Inc had 2 analyst reports since March 8, 2018 according to SRatingsIntel. As per Thursday, March 8, the company rating was maintained by Robert W. Baird.

The stock decreased 35.20% or $6.22 during the last trading session, reaching $11.45. About 6.87 million shares traded or 1705.63% up from the average. Jounce Therapeutics, Inc. (JNCE) has declined 9.84% since May 18, 2017 and is downtrending. It has underperformed by 21.39% the S&P500.

Analysts await Jounce Therapeutics, Inc. (NASDAQ:JNCE) to report earnings on August, 8. They expect $-0.38 EPS, down 245.45 % or $0.27 from last year’s $-0.11 per share. After $-0.40 actual EPS reported by Jounce Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -5.00 % EPS growth.

Jounce Therapeutics, Inc., a clinical stage immunotherapy company, focuses on developing therapies that enable the immune system to attack tumors. The company has market cap of $371.94 million. The Company’s lead product candidate, JTX-2011, is a clinical stage monoclonal antibody that binds to and activates ICOS, a protein on the surface of certain T cells commonly found in various solid tumors. It currently has negative earnings. The firm is also developing JTX-4014, an anti-PD-1 antibody.

More notable recent Jounce Therapeutics, Inc. (NASDAQ:JNCE) news were published by: Nasdaq.com which released: “Mid-Morning Market Update: Markets Edge Higher; Walmart Tops Q1 Views” on May 17, 2018, also Streetinsider.com with their article: “Pre-Open Movers 05/17: (WWE) (LOXO) (NTES) Higher; (JNCE) (JCP) (ACXM) Lower (more…)” published on May 17, 2018, Benzinga.com published: “Benzinga’s Daily Biotech Pulse: ASCO Abstracts, Fibrocell, Ispen And More” on May 17, 2018. More interesting news about Jounce Therapeutics, Inc. (NASDAQ:JNCE) were released by: Nasdaq.com and their article: “Jounce Therapeutics to Present Data from Ongoing ICONIC Trial of JTX-2011 at the 2018 American Society of Clinical …” published on May 16, 2018 as well as Seekingalpha.com‘s news article titled: “Premarket analyst action – healthcare” with publication date: May 17, 2018.

Jounce Therapeutics, Inc. (NASDAQ:JNCE) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: